Extended Data Fig. 1: Anti-Nucleocapsid Protein IgG Antibody Response to mRNA SARS-CoV-2 Vaccination in Persons With and Without Prior SARS-CoV-2 infection.
From: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
Box plots display the median values with the interquartile range (lower and upper hinge) and ±1.5-fold the interquartile range from the first and third quartile (lower and upper whiskers). We used two-sided Wilcoxon tests, without adjustment for multiple testing, to conduct the following between-group comparisons: (1) infection naïve (n = 903) and those with prior infection (n = 78), both at baseline (P < 0.001); (2) infection naïve (n = 490) and those with prior infection (n = 35), both following dose 1 (P < 0.001); (3) infection naïve (n = 228) and those with prior infection (n = 11), both following dose 2 (P < 0.001); (4) infection naïve (n = 490) following dose 1 and those with prior infection (n = 78) at baseline (P < 0.001); and, (5) infection naïve (n = 228) following dose 2 and those with prior infection (n = 35) following dose 1 (P < 0.001).
